(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 December 2005 (29.12.2005)

PCT

(10) International Publication Number
WO 2005/124361 A3

(51) International Patent Classification:
G01N 33/556 (2006.01) *C07K 14/705* (2006.01)

(21) International Application Number:
PCT/GB2005/002434

(22) International Filing Date: 21 June 2005 (21.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0413872.3	21 June 2004 (21.06.2004)	GB
60/586,618	9 July 2004 (09.07.2004)	US
0423327.6	20 October 2004 (20.10.2004)	GB
60/620,854	21 October 2004 (21.10.2004)	US

(71) Applicant *(for all designated States except US)*: **PARADIGM THERAPEUTICS LIMITED** [GB/GB]; 162 Cambridge Science Park, Milton Road, Cambridge CB4 0GP (GB).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **APARICIO, Samuel** [PT/GB]; Paradigm Therapeutics Limited, 162 Cambridge Science Park, Milton Road, Cambridge CB4 0GP (GB). **DIXON, John** [GB/GB]; Paradigm Therapeutics Limited, 162 Cambridge Science Park, Milton Road, Cambridge CB4 0GP (GB). **HENDRICK, Alan** [IE/GB]; Paradigm Therapeutics Limited, 162 Cambridge Science Park, Milton Road, Cambridge CB4 0GP (GB). **HORWOOD, Jennifer, Marie** [GB/GB]; Paradigm Therapeutics Limited, 162 Cambridge Science Park, Milton Road, Cambridge CB4 0GP (GB). **ZAHN, Dirk** [DE/GB]; Paradigm Therapeutics Limited, 162 Cambridge Science Park, Milton Road, Cambridge CB4 0GP (GB).

(74) Agents: **KHOO, Chong-Yee** et al.; D Young & Co, 120 Holborn, London EC1N 2DY (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,

[Continued on next page]

(54) Title: USES OF GPR100 RECEPTOR IN DIABETES AND OBESITY REGULATION



(57) Abstract: We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO. 5, or a sequence which is at least 90% identical thereto.

WO 2005/124361 A3

OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*

(88) Date of publication of the international search report:
27 April 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.